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Summary
Purpose. To prospectively compare the ability of clinical examination, mammography, vascularity-sensitive
ultrasound, and magnetic resonance imaging (MRI) to determine pathologic complete response (CR) in breast
cancer patients undergoing neoadjuvant chemotherapy.
Patients and methods. Participants were women with primary measurable, operable invasive breast cancer (Stages
I–III) who presented to the University of Michigan Breast Care Center. Eligibility criteria were based on clinical
need for chemotherapy as part of the overall treatment plan. The chemotherapy consisted of doxorubicin and
docetaxel administered every 3 weeks for four cycles. Tumor size measurements by physical examination and by the
three imaging modalities were performed before chemotherapy was initiated and after its completion, prior to
definitive surgery. Response criteria were pre-specified in this prospective design, and study radiologists analyzed
the mammographic, sonographic and MRI image sets blinded to information from the other modalities and blinded
to final histological diagnosis. The pathologic CR rate obtained by the clinical and imaging modalities was com-
pared to pathologic CR as determined pathologically.
Results. 41 of 43 enrolled patients had a determination of pathologic response, and 4 patients had a pathologic
CR to this chemotherapy (9.8%). The accuracy of physical examination, mammography, ultrasound, and MRI in
determining pathologic CR was 75, 89, 82, and 89% respectively (NS).
Conclusion. Biopsy after neoadjuvant chemotherapy remains absolutely necessary to determine pathologic CR to
neoadjuvant chemotherapy, as the accuracy of current imaging modalities is insufficient to make this determination.
The accuracy of mammography, vascularity-sensitive ultrasound, and MRI were not observed to be significantly
different.
Introduction
Adjuvant systemic therapy reduces mortality in patients
with newly diagnosed breast cancer. Recent clinical tri-
als have shown that preoperative, or neoadjuvant, che-
motherapy is equally effective as adjuvant chemotherapy
and can result in a higher incidence of breast preserva-
tion [1, 2]. However, selection of candidates for breast
conservative therapy after neoadjuvant chemotherapy is
not always straightforward. Physical examination may
suggest a complete response to therapy, while mam-
mography shows extensive residual calcifications and
sometimes even increased calcifications [3, 4]. Develop-
ment of sensitive and specific clinical imaging methods
that can determine whether there is residual disease
could spare patients who had a complete pathologic
response from having further surgery. For those patients
with residual disease, accurate delineation of residual
cancer could simplify the selection of candidates for
breast conservation therapy, thereby reducing the
number of lumpectomy procedures with positive mar-
gins by identifying those patients who still have exten-
sive disease following chemotherapy [5].
In addition to enhanced breast preservation rates,
neoadjuvant chemotherapy permits observation of
chemoresponsiveness of the tumor. Patients with tumors
that are highly chemotherapy sensitive, as measured
by the ability of a chemotherapy regimen to induce
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pathologic complete response (CR), have improved
long-term disease free survival [6–9]. Ideally, a patient’s
response to neoadjuvant chemotherapy could be used to
individually tailor systemic treatment, although the
clinical benefit of this approach has not yet been proven.
Non-invasive imaging methods that can accurately
determine pathologic CR after a short course of che-
motherapy would be of great value in the execution of
clinical trials that test the utility of assigning different
treatment type or duration based on response to neo-
adjuvant chemotherapy.
Common imaging modalities used in the evaluation
of patients with primary breast cancer include mam-
mography, ultrasound, and magnetic resonance imaging
(MRI). There is extensive literature on the use of these
three modalities in measuring breast primary tumors
and the extent of residual disease after chemotherapy
[4, 10–27]. However, we found no study to prospectively
evaluate the ability of imaging to predict pathologic CR
following neoadjuvant chemotherapy. In this prospec-
tively designed study, the primary goal was to compare
the ability of MRI, vascularity-sensitive ultrasound,




Eligible patients were women with primary measurable,
operable invasive breast cancer (clinical T1, 2, 3; N0, 1,
2; M0), based on tumor-nodes-metastases (TNM) Cri-
teria as detailed in Handbook for Staging of Cancer,
American Joint Committee on Cancer, 5th Edition, and
confirmed by core needle biopsy. Tumor size was
required to be ‡1 cm. Immunohistochemical staining for
estrogen receptor, progesterone receptor, and Her-2 neu
were obtained on the initial diagnostic sample. Patients
had an ECOG Performance status of 0–2, and were in
good general health with normal complete blood count
and comprehensive metabolic profile. Patient charac-
teristics are outlined in Table 1.
Patients were excluded if their breast tumors were not
measurable by any of the modalities, including mam-
mography, ultrasound, and MRI, or if the tumor was
diagnosed by incisional biopsy that did not leave mea-
surable disease by at least onemodality. Patients could not
have received any prior chemotherapy, radiation therapy,
or tamoxifen therapy for their current breast cancer.
All patients signed an informed consent regarding the
experimental nature of this therapy after approval by the
University of Michigan Institutional Review Board.
Treatment plan
Diagnosis and staging
Patients presented for evaluation at the Breast Care
Center at the University of Michigan. The plan for
neoadjuvant chemotherapy was approved by the Breast
Care Center’s multidisciplinary Tumor Board. All pa-
tients had primary breast tumor measurements by pal-
pation performed by their physician at the time of initial
presentation.
In patients felt to be potential candidates for con-
servative therapy after neoadjuvant treatment, either a
titanium clip was placed in the tumor, or a small tattoo
was placed over the palpable mass to guide later
excision.
Procedures for response evaluation
Physical examination and tumor size measurements
were performed on day one of each cycle of chemo-
therapy and at the end of chemotherapy before sur-
gery. The three imaging modalities (mammography,
vascularity-sensitive ultrasound, and MRI) were per-
formed at baseline (before chemotherapy was initiated)
and at the end of the fourth cycle of chemotherapy,
before definitive surgery. Radiologists analyzed the
mammographic, sonographic and MRI image sets
blinded to information about these cases from the
other modalities and additionally blinded to final his-
tological information at excision. The response criteria
as defined prospectively for each modality are
presented in Table 2.





Size of tumor (physical examination)
£ 2.0 cm 6 14
2.1–5.0 cm 23 53
‡5.1 cm 13 30















Invasive ductal carcinoma 29 67
Invasive lobular carcinoma 3 7
Anaplastic 6 14
Mixed ductal and lobular 2 5
Not otherwise specified 3 7
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Mammography
Each patient received diagnostic mammography,
which included two mammographic views of the in-
volved breast (craniocaudal, mediolateral oblique) and
additional views (mediolateral, spot magnification
views) as clinically indicated. Measurement in three
dimensions was performed manually by an experienced
FDA certified radiologist. The mammographic views
showing the best delineation of tumor margins were
used for subsequent measurements. For masses, perim-
eter margins were used. For calcifications, the greatest
extent is measured in each projection. These cases were
analyzed by a single reader (MAH).
MRI
MRI examinations were performed on a 1.5 Tesla
General Electric (GE) magnet, using a Medrad dual-
phased array dedicated breast coil for optimal resolution
and signal to noise ratio. Three dimensional volume
acquisition gradient echo sequences were performed
with fat saturation before and after the intravenous
administration of 0.15 mmol/kg gadolinium. A hybrid
sequence was used of rapid dynamic imaging combined
with high resolution imaging. Dynamic imaging was
performed using 30 s intervals for 8 min, in addition to
an intervening high resolution sequence performed at
4.5 min. Using this method, signal enhancement curves
were generated at a workstation for areas of known
tumor, and also for additional unsuspected areas of
suspicious abnormal early rapid vascular enhancement.
Thus, previously unsuspected multifocal disease, based
on physical examination and mammography, were also
assessed for response to chemotherapy. Tumor volume
was measured from 3D angiogram data constructed
from subtraction data of dynamic early enhancement
images minus the immediately preceding non-contrast
images. Occasionally, on post chemotherapy studies, 3D
angiogram was constructed from later dynamic images
due to ‘slowing’ of uptake of contrast in response to
chemotherapy in a lesion with persistent suspicious
morphology. Subjective tumor morphology was char-
acterized using descriptors defined by Abraham et al.
[28]. Non-enhancing masses were considered non-sus-
picious.
To determine tumor response to chemotherapy, the
respective post-therapy MRI tumor enhancement vol-
umes were compared to the pre-therapy breast MRI
tumor enhancement volume by a single reader (KAH
and/or CP). Residual tumor enhancement volume may
have been less than the total residual tumor volume as
determined by T1 and T2 weighted imaging. Residual
volume of enhancement, hypothesized to represent
residual metabolically active disease, was distinguished
from the larger volume seen on non-contrast imaging
composed of tumor and post treatment tumor fibrosis.
Ultrasound
Vascularity-sensitive ultrasound was performed in
each patient. In each study, the mass was localized and
imaged in three dimensions (3D) with a GE Logiq 700
scanner. The skin over the breast mass was coated with a
warmed, non-staining ultrasound scanning gel and the
breast was stabilized by stretching a two mil polyethyl-
ene film, coated with ultrasonic coupling gel, across the
chest. The film was coated externally with gel and the
breast was scanned in 3D by a combination of high
resolution gray scale and color flow imaging. The
compact hand-driven scanner depicted in [29] was em-
ployed along with the 739 L (7.5 MHz, 40 mm linear)
scanhead. For large, highly attenuating lesions, the
lower-frequency, wide field of view GE M7, 3–7 MHz,
slightly curved matrix array was used. Both whole-vol-
ume gray scale and color Doppler image sets were ac-
quired using the methods described by Bhatti et al. [30].
The same procedure was performed after four cycles of
chemotherapy. The radiologist (MAR) selected the mass
in each image volume and the volume and vascularity of
the masses were computed using the method described
previously [30].
Chemotherapy regimen
The chemotherapy consisted of doxorubicin 50 mg/m2
intravenously (IV), and docetaxel 75 mg/m2 IV, 15–
30 min after administration of doxorubicin and infused
over 1 h, on day one every 3 weeks for four cycles. Pa-
tients received premedication with dexamethasone, 8 mg
twice daily for 3 days, beginning the day prior to che-
motherapy. Antiemetics included a serotonin antago-
nist, dexamethasone, and a phenothiazine derivative.
Either filagrastim or pegfilagrastim were used prophy-
lactically after experience with the first 15 patients sug-
gested a high rate of neutropenic fever. Patients had
repeat physical examination by the same physician on
day one of each cycle of chemotherapy. Chemotherapy
was delivered for the full four cycles as long as there was
no undue toxicity, and there was no evidence of disease
progression on physical examination.
Post-chemotherapy surgical management
Each case was discussed again at the Breast Care Center
multidisciplinary Tumor Board, and final recommen-
dations for mastectomy versus breast preservation were
made. Results of the imaging studies were available to
the clinicians and were used to make the surgical deci-
sion.
All patients who underwent breast preservation had
to achieve negative surgical margins or else undergo
mastectomy. Patients who chose breast preservation
also received radiation therapy (RT) to the breast.
Among patients who presented with microcalcifications,
a post-biopsy mammogram showing no residual mic-
rocalcifications was required before proceeding to RT to
the breast. Patients with clinically positive nodes prior to
chemotherapy, or with a positive node at time of pre-
treatment sentinel node biopsy, had a Level I and II
axillary node dissection at the completion of chemo-
therapy and received regional nodal radiation after
surgery and chemotherapy were completed.
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Statistical analysis
This trial was designed to compare the ability of mam-
mography, vascularity-sensitive ultrasound, MRI, and
physical examination to predict pathologic CR. In the
original study design, it was assumed that mammogra-
phy had a 78.6% probability of correctly identifying
pathologically determined complete responders or
pathologically determined non-responders [3]. In order
to have 90% power to detect an improvement of 15%
beyond the 78.6% anticipated success rate using mam-
mography, the study was to accrue 104 patients.
An unplanned review of the data conducted after 43
patients were evaluated suggested that the proportion of
patients achieving a complete pathological response was
low (approximately 10%); and that the agreement be-
tween the diagnosis of response from the tumor mea-
suring modalities and the confirmed pathological
responding patients was so low that the original study
objective as stated could not be reached regardless of
sample size. Therefore, the study was closed to further
accrual. This manuscript describes the treatment expe-
rience of these 43 patients, the response rates, and the
experience with the use of multiple imaging modalities in
identifying complete pathologic response.
McNemar’s test of dependent proportions was used
to compare response diagnoses between physical exam-
ination and the imaging modalities with pathologically
determined response. Responses were dichotomized to
complete response versus non-complete response for
each modality. Exact p-values for the test statistics were




Between November 2000 and December 2002, 43 pa-
tients were enrolled on this study. All but 1 of the 43
patients received all four cycles of chemotherapy (cycle
delivery = 99.1%). The patient who did not receive the
fourth cycle was suspected to have progressed on
physical examination, but on subsequent evaluation of
the surgical specimen a liquid-filled tumor was found.
Response by imaging modalities
The prospectively determined response definitions are
summarized in Table 2. The overall clinical response
rates (CR + PR) as measured by each imaging modal-
ity and physical examination were very similar, at 74–
78% (Table 3). Overall, there were no significant differ-
ences in the proportions of the diagnosed response cat-
egories by the imaging modality when compared to
pathologically determined response, although statistical
power was an issue in detecting differences. In evaluable
patients, physical examination was more likely to
indicate a complete clinical response than were any of
the imaging studies In fact, in 36 patients who com-
pleted both examinations, physical examination was
significantly more likely to diagnose complete response
(30.6%) than was MRI (5.6%) (p=0.004). However, in
common patients the diagnoses by physical examination
were observed to be similar to those for mammography
(n=39, p=0.11) and ultrasound (n=40, p=0.07).
Pathologic complete response
The study was originally designed to compare the ability
of mammogram, vascularity-sensitive ultrasound, MRI,
and physical examination to distinguish between path-
ologic CR and non-CR of the breast tumors. Forty-one
of forty-three evaluable patients had a determination of
pathologic response, and four patients had a pathologic
CR in the breast to this chemotherapy (9.8%). This rate
is nearly identical to rates in previously reported studies
using a similar regimen [31, 32]. There was only one case
in which all four modalities predicted pathologic CR
and pathologic CR was present. In three other cases of
pathologic CR, extensive fibrosis or biopsy site changes
were present on final pathological review, which may
have affected the specificity of the radiologic findings.
The accuracy of each modality in distinguishing
pathologic CR versus non-CR for those patients who
had measurable disease by the modality is reported in
Table 4. The sensitivity of physical examination, mam-
mography, ultrasound, and MRI for detecting a path-
ologic CR was 50, 50, 25, and 25%, respectively. The
specificity (those patients without a pathologic CR for
whom the modality suggested residual disease) was 78,
94, 89, and 97%, respectively. The overall accuracy of
physical examination, mammography, ultrasound, and
MRI in predicting pathologic CR was 75, 89, 82, and
89%. In this regard, the positive predictive values (that a
negative study predicted for pathologic CR) for physical
examination, mammography, ultrasound, and MRI
were 2/10 (20%), 2/4 (50%), 1/5 (20%), and 1/2 (50%).
The negative predictive values (that a positive study
predicted for pathologic NCR) were 93, 94, 91, and
94%, respectively.
Discussion
In this study we explored the ability of clinical modali-
ties to predict pathologic complete response in the
breast, because accurate prediction of pathologic CR, as
opposed to a clinical CR or PR, may (1) define a subset
of patients who do not need a surgical procedure after
neoadjuvant chemotherapy or (2) define a subset of
patients with a worse/better prognosis who would/
would not benefit from additional systemic chemother-
apy. However, even with state-of-the-art breast MRI
and vascularity-sensitive ultrasound, we were not able to
accurately predict pathologic CR. In over half of the
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cases where pathologic CR was achieved, the imaging
modalities still suggested residual cancer.
Prior studies evaluating the use of mammography,
ultrasound, MRI, and clinical examination in neoadju-
vant chemotherapy have shown that imaging modalities,
particularly MRI, can predict the size of residual disease
following neoadjuvant chemotherapy [5, 13, 26, 27, 33].
Other studies have shown that use of imaging early on in
treatment can predict response to the prescribed therapy
[22, 24]. These studies were based on the premise that
such predictions would lead to early changes in therapy
and would benefit patients. However, the responses
predicted by imaging in these studies were not patho-
logic CRs, and responses short of pathologic CR are not
surrogates for meaningful clinical benefit such as disease
free or overall survival. It is doubtful that use of imaging
technology to predict partial responses will lead to
improvement in patient outcomes.
Several previous papers have suggested that MRI is
the most accurate imaging modality in measuring re-
sponse to chemotherapy. In general, these studies were
looking at the absolute measurement of residual disease
and not the attainment of pathologic CR. The ‘superi-
ority’ of MRI in such studies is expected due to its high
sensitivity and low specificity for residual disease in a
patient population unlikely to achieve pathologic CR. It
is likely that MRI will be less accurate in a dataset with a
higher pathologic CR rate, and so it may be worthwhile
to re-examine the relative accuracy of these imaging
methods for detection of pathologic CR within a patient
population more likely to achieve pathologic CR. For
example, it has been shown that more prolonged che-
motherapy regimens of anthracyclines and taxanes have
pathologic CR rates of 25–30% [34], and a recent study
using trastuzumab in the neoadjuvant setting for Her-2
neu positive patients reported a complete pathologic
response rate of 67% [35] (Abstract). Additionally, ad-
vances in gene expression profiling may make it possible
to select for study those patients with a higher likelihood
of complete pathologic response [36, 37].
These imaging modalities performed best in negative
prediction (identifying when pathologic CR was not
achieved). Assuming that (1) pathologic CR is a desired
goal prior to surgery in order to optimize patient out-
comes, and (2) longer durations of therapy may be more
effective in producing pathologic CR, one potential use of
breast imaging in neoadjuvant chemotherapy may be to
determine those patients who did not have a pathologic
CR after induction chemotherapy, and to offer these
patients more therapy prior to definitive surgery. Re-
cently completedmulti-institutional trials of neoadjuvant
chemotherapy, such as the National Surgical Adjuvant
Breast Project’s trial NSABP B-27 [34], will help to
establish whether patients who do not achieve pathologic
CR to four cycles of chemotherapy will benefit from
additional chemotherapy. However, given the significant
false-positive rate of imaging in our study, such a use
should be combined with image-directed biopsy to con-
firm the continued presence of viable tumor.
We conclude that biopsy after neoadjuvant chemo-
therapy remains absolutely necessary to determine
pathologic CR to short courses of neoadjuvant
Table 3. Breast tumor responses as measured by each modality
Pathology Physical exam Mammography Ultrasound MRI
Complete response 4/41 (9.8%) 11/41 (27%) 4/39 (10%) 5/40 (13%) 2/36 (6%)
Partial response NA 20/41 (49%) 25/39 (64%) 25/40 (63%) 26/36 (72%)
Stable disease/Pathologic NCR 37/41 (90.2%) 10/41 (24%) 8/39 (20%) 8/40 (20%) 7/36 (19%)
Progressive disease NA 0/41 (0%) 2/39 (5%) 2/40 (5%) 1/36 (3%)
Response rate (CR + PR) NA 76% 74% 76% 78%
Study performed and evaluable 41/43 (95%) 41/43 (95%) 39/43 (91%) 40/43 (93%) 36/43 (84%)
Not evaluable by this modality 2/43a (5%) 1/43 (2%) 4/43 (9%) 3/43 (7%) 1/43 (2%)
Study not performed 0/43 (0%) 1/43 (2%) 0/43 (0%) 0/43 (0%) 6/43 (14%)
aOne patient received 2 additional cycles of chemotherapy, one patient after review could not be confirmed to have a breast mass separate from
the lymph nodes.
Table 4. Concordance between the pathologically determined response and the diagnosis by tumor measurement modality
Pathologic response Modality, n (%)
Physical exam Mammography Ultrasound MRI
CR 2/4 (50%) 2/4 (50%) 1/4 (25%) 1/4 (25%)
NCR 28/36 (78%) 32/34 (94%) 31/35 (89%) 30/31 (97%)
Overall agreement 30/40 (75%) 34/38 (89%) 32/39 (82%) 31/35 (89%)
Positive predictive value for pathologic CR 2/10 (20%) 2/4 (50%) 1/5 (20%) 1/2 (50%)
Negative predictive value for pathologic CR 28/30 (93%) 31/34 (94%) 31/34 (91%) 31/33 (94%)
CR=complete response.NCR=non-complete response.
236 AF Schott et al.
chemotherapy, as the accuracy of current imaging
modalities is insufficient to make this determination. It is
possible that imaging modalities could play a role in
identifying patients without a pathologic CR, who may
benefit from a longer and/or modified neoadjuvant
treatment regimen, in combination with imaging-direc-
ted core biopsy. This role of imaging should be tested
prospectively in a patient population treated with a
regimen that is expected to result in a higher pathologic
CR rate.
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